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Natural killer cells are cytotoxic innate lymphoid cells that play an important role for
early host defenses against infectious pathogens and surveillance against tumor. In
humans, NK cells may be divided in various subsets on the basis of the relative CD56
expression and of the low-affinity FcγRIIIA CD16. In particular, the two main NK cell
subsets are represented by the CD56bright/CD16−/dim and the CD56dim/CD16bright NK
cells. Experimental evidences indicate that CD56bright and CD56dim NK cells represent
different maturative stages of the NK cell developmental pathway. We identified multiple
miRNAs differentially expressed in CD56bright/CD16− and CD56dim/CD16bright NK cells
using both univariate and multivariate analyses. Among these, we found a few miRNAs
with a consistent differential expression in the two NK cell subsets, and with an
intermediate expression in the CD56bright/CD16dim NK cell subset, representing a
transitional step of maturation of NK cells. These analyses allowed us to establish the
existence of a miRNA signature able to efficiently discriminate the two main NK cell
subsets regardless of their surface phenotype. In addition, by analyzing the putative
targets of representative miRNAs we show that hsa-miR-146a-5p, may be involved
in the regulation of killer Ig-like receptor (KIR) expression. These results contribute
to a better understanding of the physiologic significance of miRNAs in the regulation
of the development/function of human NK cells. Moreover, our results suggest that
hsa-miR-146a-5p targeting, resulting in KIR down-regulation, may be exploited to
generate/increment the effect of NK KIR-mismatching against HLA-class I+ tumor cells
and thus improve the NK-mediated anti-tumor activity.
Keywords: NK cells, miRNA, KIR, CD56bright, CD56dim, NK cell subsets, miRNA microarrays, multivariate
statistical analysis
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INTRODUCTION
Natural killer (NK) cells are crucial effectors in the immune
response against pathogen infection, in tumor surveillance and
in regulating immune homeostasis (1). NK cells develop in
the bone marrow and complete their maturation in peripheral
organs. The total population of human NK cells is phenotypically
and functionally heterogeneous. In physiological conditions,
the distribution/intensity of the surface markers CD56 and
CD16 (FcγRIIIA) defines two NK lymphocytes subsets: the
CD56bright/CD16−/dim population that makes up about 10%
of peripheral blood NK cells and the CD56dim/CD16bright
subset that represents about 90% of circulating NK cells (2).
The CD56bright/CD16− NK cell subset represents 50–70% of
CD56bright, whereas the CD56bright/CD16dim cells are ∼30–
50% of CD56bright (3, 4). Additional NK cell populations exist
but are a minority in healthy individuals. These include the
CD56dim/CD16− (whose function is largely unknown) (5) and
the functional CD56−/CD16bright NK cell subsets. This last subset
is often expanded during certain viral infections, but it is usually
hyporesponsive under these conditions (6–9).
CD56bright NK cells exert limited cytotoxic capacity, but
produce abundant cytokines such as IFN-γ, TNF-α, and GM-
CSF. For this ability, this subset has been generally referred
to as regulatory NK cells. Conversely, CD56dim NK cells are
highly cytotoxic (they contain much more perforin, granzymes
in cytolytic granules) and play a key role in natural and
Ab-mediated cell cytotoxicity. Nevertheless, subsequent data
indicated that they can also produce relatively high amounts
of pro-inflammatory cytokines following the engagement of
activating NK receptors (10). The different functional outcomes
of CD56bright and CD56dim NK cells are dependent on different
repertoires of activating (11) and inhibitory receptors (12) and
on distinct homing capacities associated with different expression
of chemokine receptors on their surface. Indeed, CD56bright and
CD56dim NK cell subsets differ in their pattern of expression of
inhibitory NK cell receptors specific for HLA-class I molecules
(13). In humans, different types of inhibitory receptors specific
for HLA-class I molecules exist: (i) killer Ig-like receptors
(KIRs/CD158), that recognize the polymorphic HLA-A, -B, and -
C molecules (12, 14, 15), (ii) the immunoglobulin-like receptor
1 (LIR-1/ILT-2/CD85j), that is specific for different HLA-class
I molecules (16), and (iii) the CD94/NKG2A (CD94/CD159a)
heterodimer, that recognizes HLA-E (17), a non-polymorphic
non-classical HLA molecule.
CD56bright NK cells are KIR− and CD94/NKG2A+, whereas
CD56dim NK cells are KIR+ and/or CD94/NKG2A+ (12, 14).
Moreover, CD56dim NK cells express CXCR1, CX3CR1, and
ChemR23 receptors, and therefore mainly migrate to inflamed
peripheral tissues, while the CD56bright subset expresses CCR7
and homes primarily to secondary lymphoid organs (18).
Accordingly, CD56bright NK cells are 10 times more frequent
Abbreviations: NK, natural killer cells; KIRs, killer immunoglobulin-like
receptors; HLA, human leukocyte antigen; NCRs, natural cytotoxicity receptors;
mAb, monoclonal antibody; miRNAs, microRNAs; RT-PCR, real time polymerase
chain reaction; PBMC, peripheral blood mononuclear cells.
in normal lymph nodes than in peripheral blood (19, 20).
Remarkably, recent data indicate that in pathological conditions
that include viral infections or tumors the CD56dim subset may
also de novo express CCR7 and migrate toward lymph nodes
(21–25).
A current hypothesis regarding their development indicates
that immature CD56bright NK cells (that are consistently
CD94/NKG2A+), are precursors of CD56dim (8). During their
differentiation process, NK cells up-regulate CD16 developing
from CD56bright/CD16− into CD56bright/CD16dim and then into
CD56dim/CD16bright NK cells. In turn, CD56dim NK cells change
their phenotypic features losing expression of CD94/NKG2A,
and successively acquiring the KIRs and LIR-1 inhibitory
receptors. The terminally differentiated phenotype of CD56dim
cells is characterized by CD57 expression that is associated with
poor reactivity to cytokine stimulation, but maintains cytolytic
capacity (26, 27). Such linear differentiation is supported by the
evidence that (i) CD56bright NK cells have longer telomeres than
CD56dim NK cells, (ii) they are more represented in peripheral
blood early after hematopoietic stem cell (HSC) transplantation,
and (iii) they differentiate into CD56dim NK cells in humanized
mice engrafted with human HSC (28, 29). However, despite
the known phenotypic and functional differences between the
two main NK cell subsets, many cellular and molecular features
governing the transition from CD56bright to CD56dim cells
remain unknown.
microRNAs (miRNAs) are a large family of small non-coding
RNAs that target the 3′-UTR of mRNAs, thereby reducing
mRNA stability and/or limiting protein translation, consequently
regulating critical cellular processes (30, 31). Recent studies have
identified miRNAs expressed in resting and activated mouse and
human NK cells, and have shown that global miRNA deficiency
results in altered mature NK cell functional responses in vitro
and in vivo. In particular, it has been demonstrated that miRNAs
regulate fundamental NK cell processes including activation in
terms of cytokine production, cytotoxicity, and proliferation,
but probably also their development and maturation (32–35).
Thus, we decided to analyze miRNA expression in different NK
cell subsets and perform a functional annotation and prediction
of putative mRNA targets in order to highlight any differences
that might be correlated with their subsequent maturation
steps.
Our analysis allowed us to establish the existence of a
miRNA signature able to discriminate the two main NK cell
subsets, regardless of their surface phenotype. Moreover, we also
identified miRNAs exclusively expressed by CD56bright/CD16−
NK cells (hsa-miR-31a-5p and hsa-miR-130a-5p), or by CD56dim
NK cells (hsa-miR-181a-2-3p). Notably, these miRNAs show an
intermediate expression in CD56bright/CD16dim NK cells. These
data strengthen the hypothesis that CD56bright/CD16− NK cells
mature toward CD56dim NK cells through an intermediate step
represented by CD56bright/CD16dim NK cells.
Importantly, our results also revealed that hsa-miR-146a-
5p, over-expressed in CD56bright NK cells, is involved in the
modulation of KIR expression, and this could result in possible
implications in the control of NK cell licensing and cytotoxicity
(36).
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Here we show for the first time differentially expressed
miRNAs in human NK cell subsets, thus providing valuable clues
for further explanation of miRNA regulation in human NK cell
maturation and suggesting their potential exploitation in NK cell
immunotherapy.
RESULTS
Univariate Statistical Method for miRNAs
Signature Identification
NK cells were negatively isolated from fresh peripheral blood
mononuclear cells (PBMC) derived from 10 different healthy
donors and then the most immature CD56bright/CD16− (referred
as CD56bright) and the mature CD56dim/CD16bright (referred
as CD56dim) NK cell subsets were sorted by the expression
of CD56 and CD16 and analyzed by flow cytometry for
different markers in order to control their purity and phenotypic
features (Figures 1A–C). As expected, CD56bright NK cells were
homogeneously CD16−, KIR−, NKG2A+, and CCR7+, whereas
CD56dim NK cells were CD16+, KIR+ and/or NKG2A+, and
CCR7−. This analysis confirmed the high purity of the two
sorted cell subpopulations. Importantly, in all instances, both
these NK cell subsets did not express the activation marker CD69
(Figures 1B,C).
Then, miRNA expression profiles of human CD56bright and
CD56dim NK cells subsets were investigated with the human
miRNA microarray kit v19.0, which allows for the detection of
a total of 2006 different human miRNA sequences (miRBase
v19.0). In particular, 10 separate samples for each of CD56bright
and CD56dim (20 total samples) were hybridized on the
arrays. The entire dataset was composed of two separately
generated microarray datasets that were analyzed together
(Supplementary File 1).
The normalized batch-corrected log2 intensity values were
used to identify miRNAs differentially expressed between the
CD56bright and the CD56dim NK cell populations (see also
Materials and Methods). Considering an arbitrary threshold of
1 light unit (1LU), 251 miRNAs were over the threshold in half or
more of the 10 CD56bright samples, 198 of which were over the
threshold in all 10 CD56bright samples. Similarly, 262 miRNAs
were over the threshold in half or more of the 10 CD56dim
samples, 213 of which were over the threshold in all 10 CD56dim
samples. Interestingly, 232 miRNAs were detectable in both NK
cell subsets and only 49 were expressed in only CD56bright (19
miRNAs) or CD56dim (30 miRNAs).
Figure 2 shows the two-color heatmap plot as result of the
unsupervised hierarchical clustering in which we performed a
bi-clustering analysis of both miRNA and NK samples. This
analysis clearly separates miRNAs differentially expressed and at
the same time CD56bright from CD56dim NK cell subset. At the
same time, we provided evidence that it is possible to separate the
twomainNK cell subsets by unsupervised hierarchical clustering.
In particular, Figure 2 represents a two-color heatmap plot
depicting the results of the bi-clustering analysis of both miRNA
and NK samples. This analysis clearly separetes CD56bright from
CD56dim NK cell subset. In particular, the heatmap identify a
first level of signature characterized by 14 up-regulated and 23
down-regulated miRNAs in the CD56dim NK cell population.
Importantly, among the most regulated miRNAs, we found 5
miRNAs deeply and homogeneously down-regulated (hsa-miR-
31-5p, hsa-miR-130a-3p, hsa-miR-223-3p, hsa-miR-146a-5p, and
hsa-miR-92a-3p) and 2 miRNAs deeply and homogeneously up-
regulated (hsa-miR-873-5p and hsa-miR-181a-2-3p) in all the
CD56dim samples compared to CD56bright ones (see arrowheads
in Figure 2). Notably hsa-miR-31-5p and hsa-miR-130a-3p
expression was below detectable levels on CD56dim NK cells,
whereas hsa-miR-181a-2-3p expression was below detectable
levels on CD56bright NK cells. These miRNAs may be considered
specific for CD56bright or CD56dim NK cells, respectively.
A Multivariate Statistical Method for
miRNAs Signature Identification
To better capture the interplay among the miRNAs in the
two cell groups (i.e., CD56dim and CD56bright), in addition
to the univariate analysis shown in Figure 2, we performed a
multivariate analysis by using the l1l2-penalized regularization
method, a machine learning technique for variable selection.
A schematic drawing in Supplementary Figure 2A shows the
approach used in such analysis (see also Materials and Methods).
The list obtained from the multivariate analysis includes all
the miRNAs found with the univariate analysis (37 miRNAs,
Figure 2) and 71 additional miRNAs identified only by this
method. Figure 3 shows the heatmap of the 108 miRNAs
signature identified (Figure 3A) and the names of the miRNAs
listed in the order used in the heatmap (Figure 3B). The result
was a miRNA signature associated with a perfect prediction
accuracy (100%, corresponding to a zero error score).
miRNA qPCR Validation of Univariate
Analysis
We selected 7 of the most regulated miRNAs (indicated in
Figures 2, 3) that were differently expressed in CD56bright and
CD56dim NK cell subsets and we validated them by quantitative
Real Time Polymerase Chain Reaction (RT-PCR). The purity of
the two NK cell subsets was confirmed by the gene expression
analysis of CCR7 (a marker selectively expressed in CD56bright
cells subset but not expressed in CD56dim NK cell subset as
shown in Figure 1C). These analyzes confirmed once again the
levels of expression of these miRNAs in the two NK cell subsets
(Figure 4A).
Then we wondered if the miRNA signature found in
the two main NK cell subsets (CD56bright and CD56dim)
could be linked to the sequential steps of maturation. Thus,
we sorted the additional NK cell subset CD56bright CD16+
(Supplementary Figure 1), that is known to represent an
intermediate step of peripheral blood-NK cell maturation, and
performed qPCR analysis by looking at the most differentially
expressed miRNAs (hsa-miR-130a-3p, hsa-miR-31-5p, hsa-miR-
181a-2-3p, hsa-miR-223-3p) (Figure 4B). We showed that the
expression levels of these miRNAs on the CD56bright/CD16+
NK cell subset were halfway between those observed on
the CD56bright/CD16− and those on the CD56dim/CD16+
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FIGURE 1 | CD56bright and CD56dim NK cell subsets isolation strategy. (A) Sorting separation strategy for CD56bright/CD16− and CD56dim/CD16+ NK cells
subsets. (B) Informative NK cell surface markers pre- and post-sorting are shown (one representative donor). (C) Post-sorting statistical analysis of informative NK
cells surface markers. Data represents the mean ± SD, n = 10 donors. T-test analysis comparing CD56bright/CD16− and CD56dim/CD16+ NK cell subsets
indicated as ****p <0.0001. Color legend: Pre-sorting NK cells are indicated in black, CD56bright/CD16− NK cells are indicated in light blue and CD56dim/CD16+ NK
cells are indicated in purple.
NK cell subsets. In particular, by comparing the qRT-PCR
data obtained from CD56bright/CD16−, CD56bright/CD16+ and
CD56dim/CD16+ NK cells subsets, the existence of a significant
progressive change in these miRNAs expression was revealed:
this detail represents the trend of NK cell subsets maturation that
shows how the expression reaches different levels as the cells goes
on maturing. (Figures 4A,B).
In addition, we also sorted the CD56dim/CD57+ and the
CD56dim/CD57− NK cell subsets, recognized as the most mature
NK cell subsets. We found that hsa-miR-130 and hsa-miR-31-
5p as well as hsa-miR-181a-2-3p were expressed at similar levels
in CD56dim/CD57+and CD56dul/CD57− NK cell subsets (data
not shown). This supports the hypothesis that such miRNAs
are important molecules for the switch between CD56bright and
CD56dim phenotypes but not for the terminal differentiation that
ends with a CD56dim/CD57+ phenotype.
miRNA Validation of Multivariate Analysis
The miRNA multivariate analysis, as reported in the sections
above, identified a signature of 108 predictive miRNAs. In order
to validate data derived by multivariate analysis, we selected 12
miRNAs composed of 6 miRNAs validated by univariate analysis
(hsa-miR-223-3p, hsa-miR-92a-3p, hsa-miR-31-5p, hsa-miR-
181a-2-3p, hsa-miR-130a-3p, hsa-miR-146a-5p) and additional 6
miRNAs identified by multivariate analysis which showed a two-
fold change listed in Supplementary Table 1: hsa-miR-215-5p,
hsa-miR-513a-5p, hsa-miR-532-5p, hsa-miR-3652, miR-6723-5p,
hsa-miR-181a-3p. This filtering procedure was undoubtedly
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FIGURE 2 | Heatmap representing the unsupervised hierarchical clustering analysis of CD56bright/CD16− and CD56dim/CD16+ NK cells miRNAs signature obtained
with the univariate analysis. Heatmap of 37 miRNAs signature identified by the human miRNA microarray kit v19.0. Dendrograms indicate the results of the
bi-clustering analysis. Table at the bottom of the figure helps with the translation between centered log2 data and fold-change values, and also introduces the heat
map color scheme used. Colored boxes indicate 7 of the most regulated miRNAs. Color legend: the most up-regulated miRNAs on CD56bright/CD16− NK cells are
indicated in light blue and the most up-regulated miRNAs on CD56dim/CD16+ NK cells are indicated in purple.
necessary to achieve a more compact and interpretable signature,
but it induced an additional verification phase on themultivariate
model. In fact, before proceeding with the validation, we had
to make sure that a multivariate model based only on the
12 miRNAs of the filtered signature was still capable of a
good prediction performance in discriminating CD56bright and
CD56dim. Therefore, we considered the original dataset limited
to the 12 selected miRNAs, obtaining a shortened dataset of 20
samples and 12 variables. Using regularized least squares in a
Monte-Carlo Cross Validation setting as in Barbieri et al. (37),
we estimated a new predictive model that was able to achieve a
99.7% average prediction accuracy and associated with a p-value
as low as 1.020e-20 from the two samples Kolmogorov-Smirnov
test (Supplementary Figure 2B). This result showed that the
12 miRNAs model is an excellent classifier of CD56bright and
CD56dim when considering miRNAs expressions measured with
the microarray technology.
We then proceeded with a further validation step with the aim
of verifying if such model was still capable of good prediction on
new samples measured with a different technology, i.e., qPCR.
This is a very strong requirement on the generalization
properties of the model, as the test set was completely
independent from the learning set, having been acquired with
a different technique and on different samples. To this aim, the
expression of the 12 miRNAs was measured on 6 new samples
(Supplementary Figure 3). We used the same statistical classifier
to predict the status (CD56bright or CD56dim) of the 6 samples
measured with qPCR obtaining a correct prediction of 4 out of 6
samples. The entire validation procedure is depicted in detail in
Supplementary Figure 2B.
Target Genes Prediction
Since miRNAs function mainly through the inhibition of target
genes, we next tried to identify the mRNA targets regulated by
miRNAs differentially expressed in human NK cell subsets that
might be involved in their function/maturation.
We considered six prediction tools for mRNA target
genes prediction: TargetScan (38), Miranda (39), MirDB
(40), Eimmo (41), Pictar (42), and PITA (31). Each
tool was used to predict the target genes regulated by
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FIGURE 3 | Heatmap representing CD56bright/CD16− and CD56dim/CD16+ NK cells miRNAs signature obtained with multivariate statistical method. (A) Heatmap of
the 108 miRNAs signature identified by the l1l2-penalized regularization method. Colored boxes indicate 7 of the most regulated miRNAs. (B) miRNAs listed in (A)
(from top to bottom) are indicated. Color legend: the most up-regulated miRNAs on CD56bright/CD16− are indicated in light blue and the most up-regulated miRNAs
on CD56dim/CD16+ NK cells are indicated in purple.
miRNAs that belongs to Supplementary Table 1, which
contains 37 selected miRNAs up-regulated on CD56dim
and 33 miRNAs up-regulated on CD56bright, on the basis
of multivariate analysis. A complete list of the potential
target genes predicted by bioinformatics platforms is
shown in Supplementary File 2 both for CD56dim and
CD56bright.
Since one of the goals of this study was the identification of
novel miRNAs that may contribute to the NK cell development
and differentiation, we focused our attention on potential
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FIGURE 4 | Quantitative RT-PCR validation of the expression of seven of the most regulated miRNAs on different NK subsets. (A) Quantitative RT-PCR validation of
the expression of miR-92a-3p, miR-146a-5p, miR-223-3p, miR-873-5p, miR-31-5p, miR-130a-3p, and miR-181a-2-3p in CD56bright/CD16− and CD56dim/CD16+
NK cell subsets. The qRT–PCR experiment was performed using samples prepared separately from the microarray experiment. Quantitative evaluation of CCR7
mRNA transcripts in human CD56bright and CD56dim NK cells by real-time RT-PCR was used as control. Data represents the mean ± SEM, n = 3 donors. T-test
analysis comparing CD56bright CD16− and CD56dim CD16+ NK cell subsets indicated as *p < 0.05, **p < 0.01, *** p <0.001. (B) Quantitative RT-PCR validation of
the expression of miR-223-3p, miR-31-5p, miR-130a-3p, and miR-181a-2-3p in CD56bright/CD16−, CD56bright/CD16+, and CD56dim/CD16+ NK cell subsets. The
qRT–PCR experiment was performed using samples prepared separately from the microarray experiment. Data represent the mean ± SEM, n = 3 donors. One way
Anova with Bonferroni’s post-test comparing the three NK cell subsets indicated as *p < 0.05, **p < 0.01. Color legend: CD56bright/CD16− NK cells are indicated in
light blue, CD56bright/CD16+ NK cells are indicated in dark blue, CD56dim/CD16+ NK cells are indicated in purple,and the miRNAs that can be considered
completely down-regulated in either CD56bright/CD16− or CD56dim/CD16+ are indicated with an orange frame.
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target genes encoding for markers that are differently expressed
on the two main NK cell subsets. These analyses identified
some miRNAs differently expressed on CD56bright compared to
CD56dim NK cells as potential regulator of targets genes encoding
molecules of our interest (Table 1).
In particular, our analysis identified hsa-miR-146a-5p as
a possible regulator of targets genes encoding for different
members of the most important HLA-I specific NK receptors, the
KIR family (12). Notably, hsa-miR-146a-5p seems to be mainly
involved in the regulation of inhibitory KIR expression (with
the exception of KIR3DL2/3), while other miRNAs appear to be
involved in the regulation of activating KIRs. The only exception
is represented by KIR3DS1 that again appears to be regulated
by hsa-miR-146a-5p (Table 1). In addition, one of the predicted
target of hsa-miR-146a-5p is perforin mRNA.
It is important to remember that KIR receptors are selectively
expressed by the CD56dim NK cell population and absent on the
CD56bright cell population [with the exception of KIR2DL4 (15)]
and that their expression increases according to the maturation
state of NK cells. Furthermore, perforin expression is higher in
CD56dim NK cell compared to CD56bright cell. In this context,
the up-regulation of hsa-miR-146a-5p detected on CD56bright
NK cells may be in line with the down-regulation of KIRs and
perforin expression on this subset.
To demonstrate that the KIR genes may represent targets for
hsa-miR-146a-5p, we performed additional experiments focusing
our attention on genes encoding the inhibitory KIR2DL1 and
KIR2DL2 receptors. These KIR receptors exhibit complementary
features to enable recognition of both HLA-C1 and HLA-C2
subtypes, the dominant KIR ligands.
Dual-Luciferase Reporter Assay to Validate
KIR2DL1 and KIR2DL2 as Targets of
miR-146a-5p
By using different target prediction software we predicted
that hsa-miR-146a-5p has conserved binding sites in the
3′UTR of KIR2DL1 (Figure 5A) and KIR2DL2 (Figure 5B). To
functionally verify the putative miRNA-mRNA interaction, we
used plasmids containing the entire 3′UTR of both KIR2DL1
and KIR2DL2 and luciferase and Renilla reporter genes. COS-
7 cells were transfected with these plasmids with hsa-miR-
146a-5p or with negative control (miR-NC). Luciferase results
revealed significant inhibition of luciferase activity for hsa-miR-
146a-5p with both 3′UTR sequences of KIR2DL1 (Figure 5A)
and KIR2DL2 (Figure 5B). Thus, we validated KIR2DL1 and
KIR2DL2 as potential hsa-miR-146a-5p targets by luciferase
reporter assay.
In silico Functional Characterization of the
Predicted Gene Targets
In order to explore which pathways characterize the predicted
gene targets, we performed a in silico functional characterization
using the webtoolkit WebGestalt (43) (see Materials and
Methods). In particular, we made the enrichment analysis
considering the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (44).
In details we found 195 common KEGG pathways, 5 pathways
specific for CD56bright and 2 pathways specific for CD56dim
(Supplementary File 3). In Figure 6 we reported a selection of
the common KEGG pathways that we considered majorly linked
to phenotypic and functional features of NK cells indicating
which of the validated miRNAs appear to be directly involved.
Among these KEGG-Pathways, we show, in particular, the
“Natural Killer cell mediated cytotoxicity” pathway (Figure 7),
where multiple putative targets of hsa-miR-146a-5p are
involved, such as CD94, HLA-C, HLA-E, Perforin, and KIRs
(including KIR2DL1/L2 that we validated as targets for this
miRNA).
DISCUSSION
Recent studies regarding the development of human NK
cell subsets showed that there is a continuum in NK-
cell differentiation in vivo from a CD56bright/CD16− to
CD56dim/CD16+ phenotype. This was demonstrated by
the detection of “intermediary” NK cell subsets, including
the CD56bright/CD16+ NK cells that display intermediate
characteristics typical of CD56bright or CD56dim cells. In
addition, some data would suggest that CD56dim cells may
change their phenotypic features continuing to differentiate
throughout their lifespan (8, 26–29). The loss of NKG2A and the
acquisition of KIRs and CD57, together with some important
functional changes, allow the definition of sequential steps of NK
cell maturation (8, 29). Several intermediates of this maturation
process are detectable in varying proportions in healthy donors.
Importantly, functional, and phenotypic perturbation of the
NK cell compartment and an unusual/aberrant redistribution
of NK cell subsets has been found in several pathological
conditions, such as inborn errors of immunity, severe chronic
viral infections, and tumors (9, 45). In this context, the
CD56dimNKG2A−KIR+LIR-1+CD57+ NK cell subset, when
derived from individuals previously exposed to pathogens,
particularly HCMV, may include “memory-like” NK cells (that
display certain functional characteristics reminiscent of adaptive
immunity cells) (7) or PD-1+ NK cells (characterized by high
surface expression of the PD-1 inhibitory checkpoint, and by
impaired anti-tumor activity) (46). However, understanding
of the molecular mechanisms that define NK cell subsets
development and function is largely incomplete.
Recently, miRNAs have been described as critical players
in the post-transcriptional regulation of gene expression,
thereby controlling many physiological processes including the
development of several immune cell lineages. Moreover, some
miRNAs have been shown to regulate both NK cell development
and function (30, 32, 33).
In order to explore whether unique miRNA profiling may
characterize NK cells with different phenotypic and functional
features, we comprehensively analyzed the functional miRNA
signatures of different NK cell subsets isolated from PBMC of
healthy donors. We could detect distinct miRNA profiles in
CD56bright and CD56dim NK cells, including unique miRNA
signatures for each subset. Among the most regulated miRNAs,
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TABLE 1 | List of some relevant NK surface marker genes targeted by specific miRNAs regulated in CD56dim and CD56bright.
List of some relevant NK surface marker genes targeted by specific miRNAs regulated in CD56dim and CD56bright
Gene Symbol miRNA upregulated on CD56dim miRNA upregulated on CD56bright
CCR7 miR-32-5p-miR-1299 miR-1-let-7e-5p-miR-125b-5p-miR-218-5p
CMKLR1 miR-7-5p-miR-32-5p-miR-373-5p-miR-873-5p miR-1-miR-17-3p-miR-18a-5p-miR-20a-3p-miR-20a-5p
miR-31-3p-miR-31-5p-miR-218-5p-miR-223-3p
CX3CR1 miR-7-5p-miR-32-5p-miR-33a-5p-miR-34a-5p
miR-132-3p-miR-362-3p-miR-873-5p
miR-1-miR-17-3p-miR-20a-3p-miR-20a-5p-miR-31-3p
miR-31-5p-miR-223-3p-miR-340-5p-miR-497-5p
CXCR1 miR-32-5p-miR-34a-5p-miR-135a-3p-miR-362-3p
miR-873-5p-miR-876-5p
miR-1-miR-31-3p-miR-31-5p-miR-135b-5p-miR-195-5p
FCGR3A miR-7-5p-miR-10a-5p-miR-32-5p-miR-135a-3p
miR-181d
miR-1-miR-133b-miR-135b-5p-miR-181a-3p
miR-218-5p
GRZB miR-1
IL2RA miR-873-5p-miR-1299 miR-1-miR-130a-3p-miR-340-5p
KIR2DL1 miR-34a-5p-miR-181d-miR-373-5p miR-1-miR-146a-5p-miR-181a-3p
KIR2DL2 miR-34a-5p-miR-181d-miR-373-5p miR-1-miR-146a-5p-miR-181a-3p
KIR2DL3 miR-34a-5p-miR-181d-miR-373-5p miR-1-miR-146a-5p-miR-181a-3p
KIR2DL4 miR-29c-5p-miR-34a-5p-miR-135a-3p-miR-210
miR-497-5p
miR-1-miR-135b-5p-miR-146a-5p-miR-195-5p
KIR2DL5A miR-34a-5p miR-1
KIR2DL5A miR-34a-5p miR-1
KIR2DL5B miR-34a-5p miR-1
KIR2DS1 miR-1
KIR2DS2 miR-34a-5p-miR-373-5p miR-1
KIR2DS3 miR-34a-5p-miR-373-5p miR-1
KIR2DS4 miR-29c-5p-miR-34a-5p-miR-373-5p miR-1-miR-133b-miR-135b-5p-miR-195-5p-miR-497-5p
KIR2DS5 miR-34a-5p miR-1
KIR3DL1 miR-34a-5p miR-1-miR-146a-5p
KIR3DL2 miR-34a-5p miR-1-miR-340-5p
KIR3DL3 miR-34a-5p miR-1
KIR3DP1 miR-873-5p miR-146a-5p
KIR3DS1 miR-34a-5p-miR-181d-miR-373-5p miR-1-miR-135b-5p-miR-146a-5p-miR-181a-3p
KLRC1 miR-1
LILRB1 miR-1-miR-17-3p-miR-20a-3p-miR-20a-5p
NCAM1 miR-10a-5p-miR-29c-5p-miR-32-5p-miR-33a-5p
miR-135a-3p-miR-152-miR-215-miR-200c-3p
miR-210-miR-362-3p-miR-505-3p-miR-505-5p
miR-873-5p-miR-876-3p-miR-876-5p-miR-1271-5p
miR-4687
miR-513a-5p
3p-miR-1-miR-17-3p-miR-18a-5p-miR-20a-3p-miR-20a-5p
miR-31-3p-miR-125b-5p-miR-146a-5p-miR-340-5p
NCR1 miR-1
NCR2 miR-132-3p-miR-181d miR-1-miR-181a-3p
NCR3 miR-32-5p
PDCD1 miR-32-5p-miR-873-5p miR-1
PRF1 miR-7-5p-miR-32-5p-miR-132-3p miR-1-miR-146a-5p
Target genes for the 70 miRNAs included in this table were predicted using six prediction tools for mRNA target genes prediction (TargetScan, Miranda, MirDB, Eimmo, Pictar, and
PITA). The table shows a selection of some of the most relevant NK cell surface marker genes with the corresponding miRNAs. The miRNAs are listed on the basis of their regulation
on CD56dim (left) and CD56bright (right). Seven of the most regulated miRNAs are indicated in bold.
three miRNAs were strongly down-regulated (hsa-miR-146a-5p,
hsa-miR-92a-3p, hsa-miR-223-3p), and one miRNA deeply up-
regulated (hsa-miR-873-5p) in CD56dim samples as compared
to CD56bright ones. Moreover, we identified miRNAs that are
exclusively expressed by CD56bright/CD16− NK cells (such as
hsa-miR-31a-5p, hsa-miR-130a-5p) or by CD56dim/CD16+ NK
cells (hsa-miR-181a-2-3p). Notably, these miRNAs display an
intermediate level of expression onCD56bright/CD16dim NK cells.
The miRNA signature identified in our study further support
the concept that CD56bright/CD16− NK cells progress toward
CD56dim NK cells through an intermediate step represented by
CD56bright/CD16dim NK cells (Figure 8).
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FIGURE 5 | Dual-luciferase reporter assay validates KIR2DL1 and KIR2DL2 as targets of miR-146a-5p. miRNA binding sites predicted by Miranda and TargetScan
within 3′UTR of KIR2DL1 (A) and KIR2DL2 (B) target genes and validation of miRNA binding. Columns represent the luciferase activity of 3′UTR plasmids containing
3′UTR of KIR2DL1 or KIR2DL2 with miR-146a-5p, relative to transfection with the same constructs and miR-NC. Relative luciferase expression (firefly normalized to
Renilla) values of hsa-miR-146a-5p were normalized to miR-NC transfected controls. Data represents the mean ± SEM, n = 3 independent experiments. One way
Anova with Bonferroni’s post-test comparing 3′UTR plasmids with miR-146a-5p to miR-NC indicated as ***p < 0.001.
FIGURE 6 | Enrichment analysis result using WebGestalt toolkit within KEGG database. The plot shows a selection of KEGG pathways shared by both CD56dim and
CD56bright NK cells. The pathways are sorted according to a score corresponding to the log transformed average adjusted p-value. Higher scores correspond to a
lowest average adjusted p-value. Crosses indicate in which pathways the putative targets of the most differentially expressed miRNAs are involved with an adjusted p
> 0.05. Color legend: P-value of the pathway corresponding to CD56dim/CD16+ NK cell subset is indicated in purple, P-value of the pathway corresponding to
CD56bright/CD16− NK cell subset is indicated in light blue; miRNAs up-regulated on CD56bright/CD16− NK cell subset and corresponding crosses are indicated in
light blue, miRNAs up-regulated on CD56dim/CD16+ NK cell subset and corresponding crosses are indicated in purple.
To the best of our knowledge, this is the first attempt to
identify a miRNAs signature capable of precisely discriminating
CD56bright and CD56dim NK cell subsets independently from
the analysis of their surface phenotype. The fact that this
signaturemay be applied to all healthy individuals, independently
from their physiological heterogeneity, makes our results even
stronger. In this regard, it is important to remember that results
published to date are frequently based on analyses of single
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FIGURE 7 | Natural Killer cell mediated cytotoxicity KEGG map. Map of the “Natural Killer cell mediated cytotoxicity” pathway derived from KEGG (hsa04650). Color
legend: genes targeted only by miRNAs overexpressed on CD56bright are indicated in light blue; genes targeted only by miRNAs overexpressed on CD56dim are
indicated in purple; genes targeted by miRNAs overexpressed on both CD56bright and CD56dim are indicated in yellow. Genes targeted by miR146a-5p are indicated
with a red outline and font.
donors. In addition, our data were validated not only by a
univariate analysis but also by means of a multivariate analysis
approach that achieved 100% average prediction accuracy
in discriminating CD56dim from CD56bright NK cells. The
validation phase was completed by testing the multivariate model
on qPCR data obtained by a different set of samples. Also this
analysis achieved a good prediction performance.
The important role of miRNAs in regulating the NK cell
function was confirmed by disruptingmiRNAs inmouse NK cells
(33). Interestingly, some recent data support a possible role of
the miRNAs identified in the present work in the functioning
of NK cells. For instance, miR-146a negatively regulates NK cell
function and its silencing has been proposed as a therapeutic
tool with a relevant potential to ameliorate the NK cell activities
in liver diseases (47). miR-223 expression is involved in the
hematopoietic cell differentiation. In particular, its expression
increases as haematopoietic progenitor cells differentiate into red
blood cells or NK cells, while a decrease was detected in cells
differentiating toward neutrophils, monocytes, megakaryocytes
and eosinophils (48). Interestingly, Granzyme B was reported
among the validated target of miR-223 in mouse (49). However,
both our target gene prediction and reports from other groups
failed to confirm this data in humans (48).
Other miRNAs involved in hematopoietic cell differentiation
belong to miR-181 family. All miR-181 contribute to the
development of all three lymphoid lineages and are involved
in human NK cell development by regulating Notch signaling
(50). In addition, miR-223, miR-130a, and miR-181 families are
deregulated during inflammatory disorders and cancer. In this
context, miR-181a expression is up-regulated in haemopoietic
malignancies and in hepatic and breast carcinomas (51).
Recent data have also revealed that miR-130a is involved
in the regulation of the activity of Nuclear factor-κB (NF-
κB), one of the most important nuclear transcription
factors involved in tumorigenesis. In particular, a negative
feedback regulation of NF-κB/miR-130a/TNF-α/NF-κB has
been described in cervical cancer cells (52). Finally, some of
these miRNAs allow discrimination between different tumor
types possibly representing a new class of blood biomarkers
(53, 54).
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FIGURE 8 | NK cells maturation and miRNAs. Hypothesis of NK cell
maturation supported by differential miRNA expression in the different NK cell
subsets. Color legend: CD56bright/CD16− NK cells are indicated in light blue,
CD56bright/CD16+ NK cells are indicated in dark blue and CD56dim/CD16+
NK cells are indicated in purple. Spot representing miR-130a-3p and
miR-31-5p that can be considered exclusively expressed by CD56bright NK
cells is indicated in light blue; spot representing miR-223-3p, miR-92a-3p,
miR-146a-5p up-regulated on CD56bright NK cells is indicated in light
blue/dark blue; spot representing miR-873a-5p up-regulated on CD56dim NK
cells is indicated in dark blue/purple and spot representing miR-181a-2-3p
exclusively expressed by CD56dim NK cells is indicated in purple.
In the present study, we also performed a prediction analysis
of putative mRNA targets. This analysis allowed us to identify
miR-146a-5p as a relevant regulator of inhibitory KIR expression
in NK cells. KIRs play a crucial role in human NK cell
development and function (12, 14, 55). Notably, KIR gene family
is absent in rodents and is present only in primates. Thus,
KIR genes were originated only recently, undergoing a rapid
evolution.
The KIR gene family currently consists of 13 KIR
genes (KIR2DL1, KIR2DL2/L3, KIR2DL4, KIR2DL5A,
KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5,
KIR3DL1/S1, KIR3DL2, and KIR3DL3) and two pseudogenes
(KIR2DP1 and KIR3DP1) encoded within the Leukocyte
Receptor Complex (LRC) located on chromosome 19 (55). Upon
recognition of specific HLA-class I ligands, inhibitory KIRs
induce signals that block NK cell function. Individual KIRs bind
distinct subgroups of HLA-class I allotypes, and are clonally
expressed in NK cells, thus generating a repertoire of NK cells
specific for different HLA-class I molecules. Dominant KIR
ligands are HLA-C allotypes. On the basis of simple diallelic
polimorphisms at position 77 and 80 of the heavy chain, HLA-C
allotypes can be distinguished in two groups. Those with
asparagine 77 and lysine 80 interact with the two Ig-like domains
KIR2DL1, while those with serine 77 and asparagine 80 interact
with KIR2DL2.
Recently, it has been shown that miR-146a-5p is involved both
in tuning the activity, intensity, and duration of inflammation
and in regulation of innate and adaptive immune responses with
implication in tumor progression, and virus infection (56–58). In
addition, miR-146a was shown to act as a negative regulator of
T (59) and NK cell function via STAT1 signaling (47). Moreover,
it negatively regulates IFN-γ production in super activated NK
cells by targeting IRAK1 and TRAF6, with subsequent inhibition
of the NF-κB signaling cascade (60).
In the present study, we predicted that hsa-miR-146a-5p has
conserved binding sites in the 3
′
UTR of KIR2DL1 and KIR2DL2.
Indeed, we could functionally verify and validate this putative
miRNA-mRNA interaction by using a dual-luciferase reporter
assay. It is well known that the genetic modification of NK cells is
notoriously difficult to be achieved. Researchers around the world
are studying different approaches to improve these techniques.
Some results have been obtained by viral transduction or
electroporation by using NK cells lines or ex vivo expanded
primary NK cells (61). However, no studies have been done on
miRNAs transfection of different NK cell subsets. Remarkably,
our luciferase reporter assay demonstrates that hsa-miR-146a-
5p could interact with the 3′UTR of the KIR2DL1/KIR2DL2
mRNA, modulating its expression. Although these experiments
were not performed on PBMC-derived NK cells, such miRNA-
mRNA interplay is clearly in accord with our data indicating that
hsa-miR-146a-5p and KIR expression was inversely correlated on
NK cells.
Interestingly, hsa-miR-146a-5p shows some putative target
sites in the 3′UTR of other KIRs and perforin (see Table 1). Based
on these findings, it will be important to functionally validate
these other putative interactions since both KIRs and perforin
play critical role in the effector function of CD56dim NK cell
subset. In this context, additional miRNAs, such as miR-27a-5p,
miR-378 and miR-30e, have been shown to interfere with NK cell
cytolytic activity by targeting the granule proteins granzyme B
and perforin (62).
Inhibitory KIRs play a central role in modulating NK
effector function by preventing NK cell activation on binding
with their ligands, primarily HLA-C molecules. KIR inhibition
has been shown to be of great clinical relevance in the
allogeneic haplo-mismatched stem cell transplantation (SCT)
model. KIR/KIR-ligand mismatch between donor and recipient
has been shown to be associated with lower rates of leukemia
relapse and higher survival (63, 64), suggesting that, in the
absence of KIR/KIR-ligand binding, “alloreactive” NK cells may
eradicate residual leukemia cells. In light of these findings,
to pharmacologically exploit NK alloreactivity, a fully human
mAb anti-KIR 1-7F9 (IPH2101) was first generated, and then
a recombinant version of this mAb was developed with a
stabilized hinge region (Lirilumab) (65, 66). A number of
evidences indicate that a high expression of KIR often correlates
with poor prognosis in patients with different solid tumors.
In addition, anti-KIR mAb increased the NK cell-mediated
lysis of HLA-I+ tumor cells. Thus, it is conceivable that this
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immunotherapeutic approach may be soon extended to non-
hematological tumors.
Recently, a novel NK cell subset referred to as “PD-1+
NK cells,” has been identified in HCMV+ individuals and in
tumor patients (46). This subpopulation, is mainly composed of
fully mature NK cells, expressing the KIR+ NKG2A− CD57+
surface phenotype, and displays a reduced capacity to kill PD-
L+ tumor cells. This impaired function is due to the surface
expression of high levels of the inhibitory checkpoint PD-1 (46).
Due to its ineffective ability to kill tumor cells, it is important
to evaluate the conditions leading to the generation of these
cells, in particular in patients with advanced cancers. In this
context, our present study indicates that hsa-miR873-5p, one the
the miRNAs up-regulated on CD56dim NK cell subset, may be
involved in the regulation of the surface expression of PD-1 (see
Table 1) with important implications in the control of NK cell-
mediated anti-tumor activity. In recent years, NK cells gained
interest as a highly attractive tool for cancer immunotherapy.
In this context, our results suggest to add hsa-miR-146a-5p
to the list of regulators of NK cell function. Indeed, this
miRNA may regulate the surface expression of KIR and, as
a consequence, the NK cell mediated cytotoxicity. Progress
in understanding the biology of NK cell subsets and of the
mechanisms regulating the expression of receptors relevant for
anti-tumor activity represents a critical key to better understand
not only the process of NK cells maturation but also to allow
NK cell manipulation to further improve their anti-tumor and
anti-viral activity. Thus, although further investigations are
required to better understand the role of hsa-miR-146a-5p and
the mechanism regulating NK cell function, these results may
provide an additional tool for a possible use of this miRNA in
tumor therapy. Accordingly, determining the miRNA expression
profile of NK cell subpopulations may provide information
on the post-transcriptional regulation mechanisms controlling
NK cell maturation and function. In conclusion, the present
study provides the first evidence of the presence of differentially
expressed miRNAs in human NK cell subsets, and offers valuable
clues for further elucidation of miRNA-mediated regulation of
NK cell maturation and function. In addition, it suggests new,mi-
RNA-based, therapeutic approaches to unleash NK cell effector
functions in the cure of cancer.
MATERIALS AND METHODS
Sample Preparation
Buffy coats from healthy donors were obtained from the
Immunohematology and Transfusion Center at the IRCCS San
Martino Polyclinical Hospital, Genoa, Italy.
All subjects gave written informed consent in accordance with
the Declaration of Helsinki. The protocol was approved by the
Ethical committee of IRCCS San Martino Polyclinical Hospital,
Genoa, Italy (39/2012).
Mononuclear cells from heparinized peripheral blood were
obtained by density gradient centrifugation over Ficoll (Sigma,
St. Louis, MO). Pure populations of NK cells were obtained
from PBMC using the NK cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s
instruction. In some experiments, MACS CD15 Micro beads
were added to further improve depletion of granulocytes. The
purity of NK cells was >98% NK cells (defined as CD56+/CD3−
CD19−/CD14−).
Freshly purified NK cells were then analyzed on BD-FACSAria
II (BD-Biosciences) and sorted based on the expression of
CD56 and CD16 molecules to collect the CD56bright/CD16−,
CD56bright/CD16dim, and the CD56dim/CD16+ NK cell subsets
separately (Figure 1 and Supplementary Figure 1). After each
sorting, a complete phenotypic analysis of the populations
collected was performed using the BD-FACSVerse (BD-
Biosciences). Sorted cells were washed in PBS and the pellet
freeze-dried (20 s in liquid nitrogen and then stored at−80◦C).
Flow Cytometry Analyses and Monoclonal
Antibodies
The following purchased mAbs were used in this
study: Anti-CD56-PC7 (clone c218), and anti-NKG2A
allophycocyanin (Z199 clone) were purchased from Beckman
Coulter/Immunotech (Marseille, France); anti-CD3-Viogreen
(BW264/56 clone), anti-CD19-VioGreen (LT20 clone), anti-
CD14-Viogreen (TÜK4 clone), and anti–KIR2DL1-S1 FITC
(11PB6 clone), mAbs were purchased from Miltenyi Biotec
(Bergisch Gladbach, Germany); anti-CD16–PerCP-Cy5.5 (3G8
clone), anti–KIR2DL2/L3/S2–FITC (CH-L clone) from BD
Bioscience; Anti-hCCR7 (IgG2a, clone 150503) was from R&D
Systems Inc (Abingdon, United Kingdom); anti-CD69 (FN50
clone, IgG1) were purchased from BioLegend (San Diego, Calif).
The anti-KIR3DL1/L2/S1 mAb (AZ158 clone) was isolated in
our laboratory and the specificity has been validated in the
corresponding patent (WO2010081890A1). Cytofluorimetric
analyses were performed on a FACSVerse (Becton Dickinson,
Mountain View, Calif), and data were analyzed with FACSuite
software version 1.0.3.
RNA Preparation
Total RNA including miRNAs was isolated using the miRNeasy
Mini Kit (Qiagen). RNA samples were quality-checked via
the Agilent 2100 Bioanalyzer platform (Agilent Technologies).
RNA integrity (RIN) was determined by means of capillary
electrophoresis by using a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, USA). The threshold for RNA
quality suitable for microarray analysis was considered to be a
RIN>6.0 (67). All RNA samples used in the microarray assays
and real-time PCR revealed RIN values between 7.6 and 9.4.
Hybridization of Human miRNA
Microarrays
Sample labeling and hybridization was performed according to
the Agilent miRNA Complete Labeling and Hyb Kit (Agilent
Technologies Santa Clara, USA) following the manufacturer’s
protocol. Briefly, 100 ng of total RNA was labeled using T4 RNA
ligase, incorporating Cyanine 3-Cytidine biphosphate (pCp).
The Cyanine-3-labeled miRNA samples were prepared for One-
Color based hybridization with complete miRNA Labeling and
Hyb Kit (Agilent Technologies, Santa Clara, USA) according
to the manufacturer’s instructions. Labeled miRNA samples
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were hybridized overnight (20 h, 55◦C) to Agilent Human
microRNAMicroarrays 8x60K v19 using Agilent’s recommended
hybridization chamber and oven. Afterwards, microarrays were
washed with increasing stringency using Gene Expression Wash
Buffers (Agilent Technologies, Santa Clara, USA). Fluorescent
signal intensities were detected with Agilent’sMicroarray Scanner
System (Agilent Technologies) and extracted from the images
using Feature Extraction 10.7.3.1 Software (Agilent Technologies,
Santa Clara, USA). For determination of differential miRNA
expression FES derived output data files were further analyzed
using the GeneSpringGX software (Agilent Technologies).
Univariate Statistical Analysis
The experimental design of this study contains groups of
matched sample pairs [CD56bright and CD56dim] obtained from
10 individuals. Therefore, statistical tests were performed to
identify miRNAs differentially expressed between the sample
groups.
The intensity data of the 10 individual microarrays were
subjected to probe summarization, thresholding (1.0), and log2-
transformation using GeneSpring v12.6 (Agilent Technologies).
Subsequently, the arrays were normalized between each other by
quantile normalization.
The miRNA data sets were normalized by quantile
normalization and base-2 logarithms (log2) intensities were
calculated. The variability between samples was visualized by
centering the normalized data relative to the median of all
samples for each miRNA. These centered data were calculated
by subtracting the median of all samples from expression value
of each individual. The recentered values are then represented
in a two-color heatmap format on a log2 scale (see also the
heatmap-coded columns median centered log2 intensities in the
Supplementary File 1). The transformed log2 intensity values
were further adjusted to reduce a batch effect. The corresponding
batch-adjusted data are provided in the table “normalized log2
data bc” within the Supplementary File 1.
These normalized batch-corrected log2 intensity values were
used in subsequent analyses to identify miRNAs differentially
expressed between the CD56bright and the CD56dim NK cell
populations. For the identification of differentially expressed
miRNAs, the robustness of detection and the statistical
significance were taken into account. With regard to statistical
significance, we applied a standard selection criteria based on the
following criteria: in the comparison of two groups, a miRNAwas
classified as induced if its Adj. p-value was ≤0.05 with difference
in the median expression level (fold-change) of at least two-fold;
a miRNA was considered repressed if its Adj. p-value was ≤0.05
with a fold-change value ≤- 2.0 (Supplementary File 2).
The unsupervised hierarchical clustering was performed
by using the online tool MORPHEUS (https://software.
broadinstitute.org/morpheus/). Specifically, Figure 2 shows the
results of the bi-clustering analysis of both miRNAs and NK cell
samples.
The data presented here have been deposited in the National
Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) with the GEO accession number GSE116743
[Internet address: (68)].
Multivariate Statistical Analysis
In supervised multivariate statistics, the goal is to model
the relationship between input data (samples) and their
corresponding labels (cell type, bright, or dim) by looking for
a function depending on several variables (miRNAs) at a time.
Such a function should be able to: (i) have good prediction
performance on the given data, (ii) generalize on previously
unseen data, and (iii) effectively describe the interplay between
the measured variables. The final outcome of a classifier is the
prediction of labels associated to a set of input examples. To assess
a prediction performance, one should define appropriate metric,
such as the accuracy score. Accuracy is defined as the ratio of
correctly predicted labels.
In this context, regularization methods are a popular class
of machine learning techniques that can be expressed as the
minimization problem of one loss function V that measures the
adherence of the objective function to the data and one or more
regularization penalites R that introduce additional information
used to solve the problem: minf V(f (X), y)+ λR(f ).
Different choices of V and R lead to different algorithms. The
parameter λ controls the trade-off between the adherence of the
model to the data and the regularity of the function f . Choosing
the regularization parameter appropriately leads to unbiased
statistical models (69). In the remainder of this section we will
illustrate the two regularization methods used in the present
work. The software library we used is implemented in Python and
publicly available at https://github.com/slipguru/palladio.
Variable Selection With Sparse Regularization
For multivariate variable selection, we chose l1l2, an embedded
regularization method that combines two penalty terms, one
enhancing sparsity (l1 norm) and the other retaining correlated
variables (l2 norm). The algorithm can be tuned to give sets
of discriminative variables of different sizes [see (70, 71) for
a detailed description of the method]. Assume we are given a
collection of n samples, each represented by a d-dimensional
vector x of measurements (e.g., the miRNAs expression vector).
Each sample is also associated with a binary label y, assigning it
to a class (e.g., CD56dim and CD56bright).
Therefore, this dataset is represented by a n× d matrix X and
a n-dimensional labels vector y. Using only a subset of the given
data (learning set), l1l2 looks for a linear model f (x) = β∗x ,
whose sign gives the classification rule that can be used to
associate a sample to one of the two classes. The classification
performance of f (x) is then assessed on the remaining samples
(test set) that were not used to build the model. The vector of
weights β∗ is forced to be a sparse vector, meaning that those
variables which have zero value will not contribute in building
the estimator f (x). The weight vector β∗ is found in the so-called
model selection phase, which consists in selecting the optimal
values for the regularization parameters.
In order to guarantee an unbiased result, model selection
and classification accuracy assessment are performed within two
nested cross-validation loops, similarly to Barla et al. (72). As
a consequence of the external loop of cross validation, l1l2
provides a set of B = 5 lists of discriminant variables (see
Supplementary Figure 2A). Therefore, it is necessary to choose
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an appropriate criterion (72) in order to assess a common list
of relevant variables. Our criterion is based on the absolute
frequency, i.e., we decided to promote as relevant the most
stable genes across the lists. The final lists of variables were
chosen according to the slope variation of the number of selected
genes vs. frequency, its value being 50%. The adoption of this
approach let us to cut out those variables not stable across the
cross-validation lists.
The l1l2 variable selection approach takes as input the entire
dataset and, following a cross validation procedure, splits it B
times in B different learning/test set pairs (blue/green rectangles).
In our experiments B was chosen equal to 5. Each split is
treated as an independent binary classification task where the
two classes are CD56bright and CD56dim, respectively. The goal
is to find a sparse predictive model based on few relevant and
predictive miRNAs out of all 2042 available miRNAs. Therefore,
for each split, the l1l2 method learns from the learning set a
statistical model via model selection and assesses its predictive
performance on the test set. The result is the prediction error and
the list of relevant variables for that particular split. Finally, the
overall prediction error is evaluated by averaging all B=5 errors.
An aggregate list of relevant variables is also provided, ranked
according to howmany times each variable has been selected over
the B= 5 splits.
Validation and Robustness Assessment
In the validation phase, we aimed at assessing if the linear
model obtained with l1l2 was still achieving good prediction
performance on a separate set of data from a different measuring
technique. After selecting the 108 relevant and possibly correlated
variables, a further selection step was performed, based on
domain expertise and current literature. This led us to a signature
of 12 miRNAs. The first step of our validation procedure
consisted in assessing if the 12 miRNAs still retained the
discriminative power of the larger set automatically selected
by l1l2. To this aim, we used PALLADIO, a machine learning
framework based on regularization methods. It provides, along
with an assessment of prediction performance, an estimate of
its reliability (37) by means of a non- parametric two samples
Kolmogorov-Smirnov test (Supplementary Figure 2B).
Microarray Data Validation by Real-Time
PCR
The microarray data was validated by real-time PCR according
to the manufacturer’s instructions (Qiagen; miScript Reverse
Transcription kit, catalog no. 218060; miScript Primer Assays
for the following miRNAs: hsa-miR-92a-3p, catalog no.
MS00006594, hsa-miR-146a-5p catalog no. MS00003535, hsa-
miR-133b catalog no. MS00031430, hsa-miR-130a-3p catalog no.
MS00003444, has-miR-31-5p catalog no. MS00003290, has-miR-
223-3p catalog no. MS00003871, hsa-miR-181a-2-3p catalog no.
MS00008834; hsa-miR-873-5p catalog no. MS00010605; hsa-
miR-181a-3p catalog no. MS00006692; hsa-miR-215-5p catalog
no. MS00003829; hsa-miR-513a-5p catalog no. MS00009912;
hsa-miR-532-5p catalog no. MS00004571; hsa-miR-3652 catalog
no. MS00023128; hsa-miR-6723-5p catalog no. MS00045794;
miScript SYBR Green PCR kit, catalog no. 218073). Then,
miRNA was normalized to the small nucleolar RNA RNU6B
(primer assay, catalog no. MS00014000). The real-time PCR
reactions were performed for target miRNAs and for the internal
reference (U6), with each sample analyzed in triplicate. For
qPCR data analysis, the 11Ct method, as previously described
by Schmittgen and Livak (73), was used to calculate the relative
expression levels of the target miRNAs. For cDNA synthesis
we used Qiagen RT2 First Strand Kit (catalog no. 330401).
RT2 PCR Assay Gene Expression was performed for CCR7
chemokine receptor 7 (NM_001838). The GAPDH was used for
normalization in the fold change expression data calculations.
After qPCR relative expression is determined with the 11Ct
method as previously described.
Target Gene Prediction Tools
Several published target prediction algorithms have been
used for the prediction of miRNA targets. Generally, such
software mainly use sequence complementarity, evolutionary
conservation among different species, and thermodynamic
criteria to estimate the probability of a miRNA:mRNA duplex
formation. For further reading, the review by Bartel published
in 2009 (30) is recommended (http://www.ncbi.nlm.nih.gov/
pubmed/19167326). For gene target prediction, we considered
six prediction tools: miRanda [http://www.microrna.org (39)],
mirDB [http://mirdb.org/miRDB/index.html (40)], Pictar
[http://http://pictar.mdc-berlin.de/[42]], PITA [http://genie.
weizmann.ac.il/pubs/mir07 (31)]. TargetScan [http://targetscan.
org (74)], ElMMo [http://www.mirz.unibas.ch/ElMMo2 (41)].
Concerning TargetScan we used the Predicted Targets (default
predictions) file belonging to the 7.0 release. Concerning PITA
we considered the PITA_sites_hg18_0_0_ALL file of the last
release (number 6). Concerning PicTar we downloaded and
used all the targets from doRiNA database (75), as suggested
in the home page of this prediction tool. Concerning miRanda
we considered the predictions from the August 2010 release.
Specifically we used the most completed file that includes
the “Non-good mirSVR Score and Non-conserved miRNAs.”
Concerning mirDB we considered the last version (5.0).
Concerning EImmo we used the last release, number 3, updated
in January 2009.
Luciferase Assay
For this purpose, we used the pEZX-MT06 target reporter
vectors containing the entire 3’UTR sequence for KIR2DL1 and
KIR2DL2 (GenBank Accession: NM_014218.2, HmiT010083-
MT06 from GeneCopoeia; GenBank Accession: NM_014219.2,
HmiT010084-MT06 from GeneCopoeia) containing putative
miR-146a-5p binding sites and transiently transfected them into
COS-7 cells by using the Lipofectamin 2000 reagents according
to the manufacturer recommendations (Invitrogen). COS-7 cells
were grown up in 24-well plates to a confluency of about 80%,
followed by a co-transfection of hsa-miR-146a-5p mimic (two
different concentrations: 36.4 nM and 54 nM, Qiagen) together
with 150 ng of each pEZX-MT06 constructs (HmiT010083-
MT06 and HmiT010084-MT06). The luciferase activity was
compared to values obtained after we co-transfected the negative
control (miR-NC, Allstars negative control, Qiagen) and the
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plasmids (HmiT010083-MT06 and HmiT010084-MT06). Forty-
eight hours after transfection, cells were lysed in 100µl of passive
lysis buffer according to the Luc-Pair Luciferase Assay Kit 2.0
(GeneCopoeia); 20 µl of the lysate was used for the luciferase
activity measurements following the instructions of the Dual-
Luciferase Reporter Assay System (Promega). Luciferase assays
were run on a LUMIstar Luminometer (BMG Labtech) in three
independent biological replicates.
Functional Characterization of the
Signature
For the functional analysis of the miRNA signature we used the
on-line gene set analysis toolkit WebGestalt (43)1WEB-based
GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic
Acids Res, 41 (Web Server issue, W77-83). The toolkit performs
the functional characterization by a gene set enrichment analysis
in several databases including KEGG (44). Given a KEGG
pathway and a reference set (such as the entire human genome)
the enrichment is based on the comparison between the fraction
of signature genes in the pathway and the fraction of pathway
genes in the reference set. The signature is enriched in the KEGG
pathway if the former is larger than the latter fraction. To perform
the enrichment analysis in KEGG, we selected the WebGestalt
human genome as reference set, p ≤ 0.05 as level of significance,
3 as the minimum number of genes, the Bonferroni correction to
correct for multiple hypotheses and the default Hypergeometric
test as statistical method.
One of the specific KEGG pathways we found enriched (NK
cell mediated cytotoxicity, hsa04650) was colored using the
“Color Pathway” tool available in KEGGMapper that is a suite of
mapping tools provided by KEGG (KEGG Copyright Permission
180201).
Statistical Analysis
Statistical analysis was performed with Graphpad Prism (La
Jolla, CA) software. For statistical analysis of cytofluorimetric
1(http://bioinfo.vanderbilt.edu/webgestalt/)
experiments (Figure 1C) and of RT-PCR data on
CD56bright/CD16−, and CD56dim/CD16+ NK cells subsets
(Figure 4A and Supplementary Figure 3) was used non-
parametric t-test (Mann Whitney test). P-value of <0.05 (∗),
<0.01 (∗∗), <0.001 (∗∗∗), and <0.0001 (∗∗∗∗) was considered
statistically significant, when not indicated, data were not
statistically significant. Multiple comparisons between RT-
PCR data on CD56bright/CD16−, CD56bright/CD16+, and
CD56dimCD16+ NK cells subsets were performed using
univariate analysis of variance (One way Anova with Bonferroni’s
post-test; Figure 4B). Cytofluorimetric experiments are reported
as the sample mean ± the standard deviation (SD) (Figure 1C)
while RT-PCR data are reported as the sample mean ±
the standard error of the mean (SEM) (Figures 4A,B and
Supplementary Figure 3).
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